Appendix I (Rose, May 2021)

BRANDON HILL CRITERIA FOR CAUSALITY SUMMARIZED:



CRITERIA 1: STRENGTH OF ASSOCIATION: Here we see a strong x-square association as see by the low P value:



CRITERIA 1: STRENGTH OF ASSOCIATION: Here we see a strong correlation as measured by a very high R value.



CRITERIA 2: CONSISTENCY: Comparing three major data bases (VAERS, Yellow Card, and EVS) we see that each show remarkably high numbers (over one million in each) of adverse events. This has never been the case in the past for any of these systems for a single product. This illustrates consistency.



CRITERIA 3: SPECIFICITY: There are specific populations known to be healthy (atheletes, and young children) who have had a spike in cardiac events explanable by the vaccine





CRITERIA 4: TEMPORALITY: These frequency time plots show 80% of all events occurring within the first few days, with frequencies well above the expected rate. The calculations yielded highly statistically significant results for deaths (p <<.001), hospitalizations (p <<.001), emergency visits (p <<.001), cardiovascular events (p <<.001), and neurologic events (p <<.001).


Jessica Rose
Data source: VAERS/Analysis: Dr. Jessica Rose
Temporality: Does A come before B?
% AEs
Injection date -> Onset AE Date
2/5/22
4. Temporality: The effect has to occur after the cause (and if there is an expected delay between the cause and expected effect, then the effect must occur after that delay)
12:50


Jessica Rose
Data source: VAERS/Analysis: Dr. Jessica Rose
Temporality
Anaphylaxis post injection
PERCENTAGE OF REPORTED AEs
NUMBER OF DAYS FOLLOWING INJECTION
Data source: VAERS Domestic Data/Analysis: Dr. Jessica Rose
YOUTH CASES 5-11 y/o post injection
PERCENTAGE OF REPORTED AEs in 5-11 yos
NUMBER OF DAYS FOLLOWING INJECTION
Data source: VAERS Domestic Data/Analysis: Dr. Jessica Rose
• 87% of reports made within 24 hours
• 92% made within 48 hours
• 73% of reports made within 24 hours
• 84% made within 48 hours
2/5/22
13:55

Figure 8.1 Time series plot — Percentage of reported deaths by time elapsed between the injection date and the reported adverse event



Figure 8.2 Time series plot — Percentage of reported hospitalizations by time elapsed between injection date and adverse event



Figure 8.3 Time series plot — Percentage of reported emergency doctor visits by time elapsed between injection and adverse event



Figure 9.1 Time series plot — Percentage of reported cardiovascular AEs by time elapsed between injection date and adverse event



Figure 9.2 Time series plot — Percentage of reported neurological AEs by time elapsed between injection date and adverse event



Another way to illustrate temporality is found on the OPENVAERS website which shows 80% of all deaths occurring within the first week after vaccination: (https://openvaers.com/covid-data)



CRITERIA 5: DOSE RESPONSE: This data showed an increase rate of myocarditis relative to the number of injections given.



CRITERIA 6: PLAUSIBILITY: Both the spike protein and the lipid nanoparticle are highly toxic (see later discussion) and provide a plausible explanation for these adverse events



The lipid nano particle contains highly toxic cationic lipids:



CRITERIA 7: COHERENCE: There is coherence between the epidemiological data and the clinical trial lab data.






Jessica Rose
Data source: VAERS/Analysis: Dr. Jessica Rose
Experiment: Is A causing B disease etiology?
The claim is that a RCT is the best way to determine if causal relationships exist -> testing if drug works with minimal bias.
2/5/22
8. Experiment: "Occasionally it is possible to appeal to experimental
25:41


Jessica Rose
Data source: VAERS/Analysis: Dr. Jessica Rose
Experiment
2/5/22
VAERS AE data for 2021 - non-COVID vs. COVID reports
900000
800000
700000
600000
500000
400000
300000
200000
100000
0
2631
798460
non_COVID
COVID
VAERS death AE data for 2021 - non-COVID vs. COVID reports
14000
12000
10000
8000
6000
4000
2000
0
36
12635
non_COVID
COVID
26:43


Jessica Rose
Data source: VAERS/Analysis: Dr. Jessica Rose
Rotavirus vaccine and intussusception
Analogy
CDC
MMWR
Weekly
Suspension of Rotavirus Vaccine After Reports of Intussusception ---United States, 1999
2/5/22
9. Analogy: The use of analogies or similarities between the observed association and any other associations.
28:23


Jessica Rose
Data source: VAERS/Analysis: Dr. Jessica Rose
Not even the placebo group did well in Moderna trials. What did they use? Saline or LNPs without mRNA payload?
Reversibility: If A stops, does B stop?
Table S24. Bell's Palsy in Overall Safety Set and By Age Group
Adverse events n (%) | Placebo | mRNA-1273 | Rate ratio | Total
Overall | N=15162 | N=15184 | | N=30346
Facial paralysis | 3 (<0.1) | 8 (<0.1) | 2.66 (0.77, 9.25) | 11 (<0.1)
≥18-<65 yrs | N=11411 | N=11415 | | N=22826
Facial paralysis | 3 (<0.1) | 5 (<0.1)* | - | 8 (<0.1)
≥65 yrs | N=3751 | N=3769 | | N=7520
Facial paralysis | 0 | 3 (<0.1)† | - | 3 (<0.1)
Serious
Facial paralysis | 0 | 1 (<0.1) | | 1 (<0.1)
Treatment-emergent adverse event (TEAE) defined as any event not present before exposure to study vaccination or any event already present that worsened in intensity or frequency after exposure. Percentages are based on the number of safety set participants. The rate ratio was calculated as the ratio of the percentage of participants who reported the event in mRNA-1273 divided by that in placebo; 95% CI was calculated using the Miettinen and Nurminen method.*1 AE severe (grade 3): male, 56 yrs, white, SARS-CoV-2 negative, not treatment-related, recovering/resolving, concomitant meds, follow-up time 2nd dose=179 days. †2 AE severe grade 3: 1) female, 67 yrs, white, SAE criteria, not treatment-related, recovered/resolved, concomitant meds, follow-up time 2nd dose=172 days and 2) male, 73 yrs, white, not treatment-related, recovered/resolved, concomitant meds, follow-up time 2nd dose=172 days. MedDRA version 23.0. Data-cutoff date: March 26, 2021.
We won't know if these products are UNSAFE until we STOP giving them to people. THAT'S JUST THE WAY IT GOES.
2/5/22
10. Reversibility: If the cause is deleted then the effect should disappear as well.
29:49